Results 211 to 220 of about 50,723 (266)

Development of predictive models for the prognosis of triple-negative breast cancer using multiple transcriptomic analyses. [PDF]

PLoS One
Hwangbo S, Choi Y, Ryu JY.
europepmc   +1 more source

Impaired glucose tolerance in women with BRCA1 versus BRCA2 pathogenic or likely pathogenic variants: Results from a prospective cohort study. [PDF]

Fam Cancer
Grandi G, Piombino C, Sighinolfi G, Barbieri E, Venturelli M, Melotti C, Lippi Bruni R, Grisendi V, Cuoghi Costantini R, Grippa M, Zattarin E, Tenedini E, Razzaboni E, Brigante G, D'Amico R, Nanni B, Menozzi R, Cortesi L, Dominici M, La Marca A, Toss A.   +20 more
europepmc   +1 more source

Decisional Conflict About Contralateral Prophylactic Mastectomy in Patients with Breast Cancer with and Without Pathogenic Variants in <i>BRCA</i> Genes. [PDF]

Cancers (Basel)
Sung JH, Katapodi MC, Park SY.
europepmc   +1 more source

Germline Pathogenic Variants in HER2-Positive Breast Cancer: Spectrum and Clinical Implications in a High-Risk Chinese Cohort. [PDF]

Cancer Med
Zhou L, Ni M, Yang A, Zhou Q, Wang D, Dun S, Xu F, Huang J, Bi X, Xia W, Hong R, Zheng Q, Chen M, Jiang K, Tang J, Wang X, Yuan Z, Wang S, Shi Y, Wang F, An X.   +20 more
europepmc   +1 more source

Identification and Characterization of Cancer-Related Risk Metabolic Subpathways Reveal Their Functional Significance in Cancer. [PDF]

Int J Mol Sci
Zhao H, Yan J, Wu M, Li S, He W, Yin X, Liu W, Liu Y, Fei M, Li W, Lv J, Chen L, Wang L.   +12 more
europepmc   +1 more source

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Issue Information

The Kaohsiung Journal of Medical Sciences, Volume 42, Issue 6, June 2026.
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

To BRCA or Not to PALB

Journal of Clinical Oncology, 2015
To BRCA or Not to PALBTO THE EDITOR: Kaufman et al1 report interesting data from anonrandomized phase II multicenter study of an oral poly (ADPribose)polymerase (PARP) inhibitor, olaparib, monotherapy in aspectrum of germline BRCA1 and BRCA 2 (BRCA 1/2) –mutatedcancers (ovarian, breast, pancreatic, and prostate cancer).
Mcnamara, Mairead; id_orcid 0000-0002-2272-3678, Lamarca, A, Hubner, RA, Valle, JW   +3 more
openaire   +3 more sources

BRCA-1, BRCA-2, and Hereditary Breast Cancer

2002
I. INTRODUCTION The etiology of breast cancer is multifactorial, involving environmental factors, hormones, genetic susceptibility, and genetic changes during progression. Mutations in a number of genes are known to cause susceptibility to breast cancer.
Betsy Bove, Roland Dunbrack, Andrew Godwin   +2 more
openaire   +2 more sources

BRCA mutations

Indian Journal of Cancer, 2022
Ovarian cancer (OC) is one of the most lethal gynecological cancers with a 5-year survival rate that ranges from 30% to 40%. Breast cancer genes (BRCA1 and BRCA2) play a key role in maintaining genomic stability. Mutations in BRCA1/2 genes lead to the accumulation of double-strand breaks, resulting in tumorigenesis.
Vineet, Talwar, Amit, Rauthan
openaire   +2 more sources